Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
van de Water W, Fontein DB, van Nes JG, Bartlett JM, Hille ET, Putter H, Robson T, Liefers GJ, Roumen RM, Seynaeve C, Dirix LY, Paridaens R, Kranenbarg EM, Nortier JW, van de Velde CJ. van de Water W, et al. Among authors: liefers gj. Eur J Cancer. 2013 Jan;49(2):297-304. doi: 10.1016/j.ejca.2012.07.026. Epub 2012 Sep 3. Eur J Cancer. 2013. PMID: 22954666 Free article. Clinical Trial.
Physical activity and survival of postmenopausal, hormone receptor-positive breast cancer patients: results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study.
de Glas NA, Fontein DB, Bastiaannet E, Pijpe A, De Craen AJ, Liefers GJ, Nortier HJ, de Haes HJ, van de Velde CJ, van Leeuwen FE. de Glas NA, et al. Among authors: liefers gj. Cancer. 2014 Sep 15;120(18):2847-54. doi: 10.1002/cncr.28783. Epub 2014 May 19. Cancer. 2014. PMID: 24840230 Free article. Clinical Trial.
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
Fontein DB, Charehbili A, Nortier JW, Meershoek-Klein Kranenbarg E, Kroep JR, Putter H, van Riet Y, Nieuwenhuijzen GA, de Valk B, Terwogt JM, Algie GD, Liefers GJ, Linn S, van de Velde CJ. Fontein DB, et al. Among authors: liefers gj. Eur J Cancer. 2014 Sep;50(13):2190-200. doi: 10.1016/j.ejca.2014.05.010. Epub 2014 Jun 23. Eur J Cancer. 2014. PMID: 24970786 Clinical Trial.
Optical mammography using diffuse optical spectroscopy for monitoring tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.
Schaafsma BE, van de Giessen M, Charehbili A, Smit VT, Kroep JR, Lelieveldt BP, Liefers GJ, Chan A, Löwik CW, Dijkstra J, van de Velde CJ, Wasser MN, Vahrmeijer AL. Schaafsma BE, et al. Among authors: liefers gj. Clin Cancer Res. 2015 Feb 1;21(3):577-84. doi: 10.1158/1078-0432.CCR-14-0736. Epub 2014 Dec 3. Clin Cancer Res. 2015. PMID: 25473002 Clinical Trial.
The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis.
Engels CC, Kiderlen M, Bastiaannet E, van Eijk R, Mooyaart A, Smit VT, de Craen AJ, Kuppen PJ, Kroep JR, van de Velde CJ, Liefers GJ. Engels CC, et al. Among authors: liefers gj. Breast Cancer Res Treat. 2016 Apr;156(2):361-70. doi: 10.1007/s10549-016-3734-y. Epub 2016 Mar 11. Breast Cancer Res Treat. 2016. PMID: 26968397 Free PMC article.
A Prospective Comparison of Younger and Older Patients' Preferences for Adjuvant Chemotherapy and Hormonal Therapy in Early Breast Cancer.
Hamelinck VC, Bastiaannet E, Pieterse AH, de Glas NA, Portielje JE, Merkus JW, den Hoed ID, van de Velde CJ, Liefers GJ, Stiggelbout AM. Hamelinck VC, et al. Among authors: liefers gj. Clin Breast Cancer. 2016 Oct;16(5):379-388. doi: 10.1016/j.clbc.2016.04.001. Epub 2016 Apr 21. Clin Breast Cancer. 2016. PMID: 27212474 Free article.
211 results